Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Intelligent Bio Solutions ( (INBS) ) just unveiled an update.
On December 31, 2025, Intelligent Bio Solutions announced a strategic manufacturing partnership with Syrma Johari MedTech to support and scale production of its Intelligent Fingerprinting Drug Screening Reader, a move aimed at strengthening global production capacity and improving profitability. Under the new arrangement, the company expects annual production cost savings of more than 40%, translating into an anticipated improvement of about 20 percentage points in gross margin compared with its previous manufacturing setup, while gaining access to manufacturing capacity roughly four times its current level. The deal diversifies INBS’s supplier base, bolsters supply-chain resilience and aligns with its global expansion plans, including a planned U.S. market entry in 2026, by leveraging Syrma Johari’s extensive, certified medical device manufacturing footprint across India, Europe and the United States and its regulatory and quality-assurance expertise across major jurisdictions.
The most recent analyst rating on (INBS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
Spark’s Take on INBS Stock
According to Spark, TipRanks’ AI Analyst, INBS is a Neutral.
The score is primarily held down by weak financial performance (persistent losses and negative cash flows) and bearish technicals (price below key moving averages with negative MACD). Valuation is constrained by a negative P/E and no dividend, while corporate events are mixed but include elevated listing-risk signals despite customer-account growth.
To see Spark’s full report on INBS stock, click here.
More about Intelligent Bio Solutions
Intelligent Bio Solutions Inc. is a Nasdaq-listed medical technology company focused on intelligent, rapid, non-invasive testing solutions. Its flagship product, the Intelligent Fingerprinting Drug Screening System, uses fingerprint sweat analysis to provide hygienic, cost-effective screening for recent use of drugs such as opiates, cocaine, methamphetamine and cannabis, with sample collection in seconds and results in under ten minutes. The company currently serves customer segments outside the U.S. in safety-critical sectors including construction, manufacturing and engineering, transport and logistics, mining, drug treatment organizations and coroners, and is positioning its technology for broader applications and geographic expansion.
Average Trading Volume: 34,893
Technical Sentiment Signal: Sell
Current Market Cap: $4.13M
For an in-depth examination of INBS stock, go to TipRanks’ Overview page.